Discover 137 paid clinical trials in Green Bay, Wisconsin. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 137
Active & Responsive
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
for
Non Small Cell Lung Cancer,
1 location in Green Bay
Sponsor: PrECOG, LLC.
Sex: All
Age: 18+
Code: NCT06538038
Recruiting
Active & Responsive
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
for
Colorectal Cancer
1 location in Appleton
Sponsor: Tempus AI
Sex: All
Age: 18+
Code: NCT05234177
Recruiting
Active & Responsive
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
for
Advanced Non-squamous Non-small-cell Lung Cancer,
1 location in Sheboygan
Sponsor: Genelux Corporation
Sex: All
Age: 18+
Code: NCT06463665
Phase2, Recruiting
Active & Responsive
WATER IV Prostate Cancer
for
Localized Prostate Cancer
1 location in Sheboygan
Sponsor: PROCEPT BioRobotics
Sex: Male
Age: 45+
Code: NCT06651632
Recruiting
Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases, PREEMPT Trial
for
Metastatic Malignant Neoplasm in the Bone,
1 location in Green Bay
Sponsor: NRG Oncology
Sex: All
Age: 18+
Code: NCT06745024
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
for
Fallopian Tube Endometrioid Adenocarcinoma,
1 location in Green Bay
Sponsor: NRG Oncology
Sex: All
Age: 18+
Code: NCT06580314
Phase3, Recruiting
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
for
Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma,
1 location in Green Bay
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: All
Age: 18+
Code: NCT04566328
Phase3, Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
for
Anatomic Stage II Breast Cancer AJCC v8,
1 location in Escanaba
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06058377
Phase3, Recruiting
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial